Psychedelics are substances (natural or laboratory made) which cause profound changes in a one’s perceptions of reality. While under the influence of hallucinogens, users might hallcuniate visually and auditorily.
This is a commonly used substance with well known effects, but that does not guarantee the substance will be safe. The safety profile has been established based on usage data commonly reported by others.
Disclaimer: Psychedelic drugs offer some of the most powerful and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.
DMT Also known as:
ine, N,N-dimethyl-[ACD/Index Name]
,N-dimethylethanami[ACD/IUPAC Name] ne
,N-diméthyléthanami[French][ACD/IUPAC Name] ne
- Indole, 3-(2-(dimet
- Indole, 3-[2- (dime
- Indole, 3-[2-(dimet
- MFCD00055989[MDL number]
- tryptamine, dimethy
- 3-[2- (Dimethylamin
- 5-22-10-00048 (Beil
stein Handbook Refe[Beilstein] rence)
- N N-DIMETHYL-1H-IND
- WLN: T56 BMJ D2N1&1
A popular and powerful psychedelic, typically used in two ways; either it is vapourised for a short ‘breakthrough’ experience, or it is taken in combination with an enzyme inhibitor for a long, intense trip (this is also known as ayahuasca or pharmahuasca).
Despite being one of the simplest psychedelic compounds, it is known for its unique ability to produce short-lived but intense visionary states and complete hallucinations. It is thought to produce its psychedelic effects by binding to serotonin receptors in the brain, although the precise mechanism is not fully understood. DMT is present in over 65 species of plants and has been identified as being a normal constituent of human metabolism and an endogenous neurotransmitter in certain rodents.
Its presence is also known to be widespread throughout the plant kingdom. Although various theories have been postulated, its neurobiological function has yet to be determined. Depending on the dosage and method of administration, the effects of DMT can range from mild psychedelic states to powerfully immersive life-altering experiences which are often described as the ultimate displacement from ordinary consciousness in which users report experiencing ineffable spiritual realms or alternate dimensions.
When vaporized or smoked, DMT produces short-lived effects with a very rapid onset that is sometimes described as an “inconceivably high-speed rollercoaster ride. " When ingested in combination with a MAOI or RIMA agent, it becomes active orally and significantly longer lasting, immersive, and interactive in nature: this combination is known as ayahuasca. Ayahuasca brews have been used traditionally in South America since at least around the year 1500.
Unlike most highly prohibited substances, DMT is not considered to be addictive or toxic by the scientific community. Nevertheless, unpredictable adverse reactions such as uncontrollable anxiety, delusions and psychosis can always occur, particularly among those predisposed to mental disorders. While these negative reactions or “bad trips” can often be attributed to user inexperience or improper preparation of set and setting, they have been known to happen spontaneously among even highly experienced users as well.
It is therefore highly advised to use harm reduction practices if using this substance.
In 1955, a team of American chemists led by Evan Horning isolated and formally identified DMT in the seeds and pods of Anadenanthera peregrina. Since 1955, DMT has been found in a host of organisms: in at least fifty plant species belonging to ten families, and in at least four animal species, including one gorgonian and three mammalian species.
Tryptamines share a core structure consisting of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain.
DMT contains two methyl groups (CH3-) bound to the terminal amine RN at the end of this chain. DMT has many homologs and analogs from base tryptamines like MET and DPT, to four and five position substituted variants such as 4-PO-DMT (psilocybin), 4-AcO-DMT (psilacetin), 5-HO-DMT (bufotenin), and 5-MeO-DMT. DMT is a white, pungent-smelling, crystalline solid.
It is insoluble in water, but soluble in organic solvents and aqueous acids.
|Avg. Mass||188.2688 Da|
|Monoisotopic Mass||188.131348 Da|
- Cannabis has an unexpectedly strong and somewhat unpredictable synergy with psychedelics.
- Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
- Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
- Tramadol is well known to lower seizure threshold and psychedelics also cause occasional seizures.
- Enhancements - Enhancements of one's auditory acuity, often following the end of the experience, have been reported in clinical studies with intravenously-administered DMT.
- Analysis enhancement
- Déjà vu
- Ego replacement
- Emotion enhancement
- Cognitive euphoria
- Feelings of impending doom
- Increased music appreciation - This typically occurs only at lower sub-breakthrough doses, and is not as prominent of an effect as it is with longer lasting psychedelics like LSD or psilocybin. Many people prefer to have their DMT experiences in complete silence, other than shutting out perceptual distractions this is often done to prevent a muddled or overwhelming experience.
- Memory suppression
- Mindfulness - This effect tends to occur after the experience has ended and the individual has returned to ordinary waking consciousness, to a sense of presence and sensitivity towards one's inner sensations as well as outer environment.
- Multiple thought streams - This effect tends to manifest in a much more chaotic fashion, in tandem with the sensation of cognitive overload.
- Novelty enhancement
- Personal bias suppression
- Rejuvenation - This effect tends to occur after the experience has ended and the subject has returned to ordinary waking consciousness, often in Near-Death Experience (NDE) variants of a DMT experience.
- Autonomous voice communication
- Time distortion - This effect is a very prominent aspect of the DMT experience, which only tends to last under 15 minutes but is commonly reported to subjectively feel as if it had lasted much longer, in some cases "many lifetimes" or even an "eternity". This particular effect is most prevalent and notable with "breakthrough" experiences.
DMT’s psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive. In addition to this, N,N-dimethyltryptamine is believed to be an endogenous ligand for the sigma receptor. However, the significance of the sigma-1 receptor remains the subject of ongoing scientific research.
- Spontaneous bodily sensations - The "body high" of DMT can be described as a pleasurable all-encompassing glow. It maintains a consistent presence that quickly rises with the onset and hits its limit once the peak has been reached. It is capable of becoming very powerful at higher doses and can remain for up to half an hour after the experience itself has ended.
- Changes in felt gravity - At higher breakthrough doses, physical feelings of being launched across vast distances at incredibly high speeds are commonly reported.
- Spatial disorientation
- Changes in felt bodily form
- Physical autonomy
- Nausea - This effect is much less common than it is with 5-MeO-DMT as well as longer-lasting psychedelics like psilocybin mushrooms or mescaline. However, it can still manifest spontaneously and sometimes lead to sudden bouts of vomiting.
- Pupil dilation
- Increased heart rate
- Temperature regulation suppression
- Seizure - This is a very rare effect but is believed to happen in those who are predisposed to them, especially while in physically taxing conditions such as being dehydrated, fatigued or undernourished.
- Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.
DMT in its smokeable form is reported to be the least mentally inebriating psychedelic. It is due to a lack of perceived intoxication that many people describe DMT as a genuine experience that is actually happening to them. It is worth noting that many people report that smoked DMT is extremely clear-headed in its style and tends to produce less personal insight in comparison to orally active psychedelics such as ayahuasca, LSD and psilocybin due to its short-acting nature.
- Drifting (melting, breathing, morphing and flowing) - In comparison to other psychedelics, this effect can be described as highly detailed, slow and smooth in motion and static in its appearance.
- Colour replacement
- Colour shifting
- Colour tinting
- After images
- Scenery slicing
- Symmetrical texture repetition
- Environmental patterning
The visual geometry encountered can be described as more similar in appearance to that of psilocin than LSD. It can be comprehensively described through its variations as intricate in complexity, abstract in form, equally organic and digital in feel, structured in organization, brightly lit, multicoloured in scheme, glossy in shading, equal in sharp and soft edges, large in size, fast in speed, smooth in motion, equal in rounded and angular corners, immersive in depth and consistent in its intensity. At higher doses, it is significantly more likely to result in states of level 8B visual geometry over level 8A.
The geometry present with smokeable DMT is considered by many to be the most profoundly intricate and complex set of visual geometry found within the entirety of the psychedelic experience. In comparison to orally active DMT (ayahuasca), it is significantly more digital in appearance and contains a colour scheme which is similar to LSD and a structured style that resembles a high dose of psilocin (4-HO-DMT).
DMT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of any other commonly used psychedelic. These effects include:
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - DMT produces high level internal hallucinations at appropriate doses more consistently than that of any other psychedelic. They are more common within dark environments and can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
- External hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - These are more common within dark environments and can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
Internationally, DMT is classified as a Schedule I controlled substance under the United Nations 1971 Convention on Psychotropic Substances, meaning that international trade in DMT is supposed to be closely monitored and its use is supposed to be restricted to scientific research and medical use. Natural materials containing DMT, including ayahuasca, are not regulated under the 1971 Psychotropic Convention.
- Nichols, David E. (2016). Barker, Eric L., ed. "Psychedelics". Pharmacological Reviews. 68 (2): 264–355. :10.1124/pr.115.011478. 1521-0081. 0031-6997.
- Ott, Jonathan (1994). Ayahuasca Analogues: Pangæan Entheogens (1st ed.). Kennewick, WA, USA: Natural Products. pp. 81–83. 978-0-9614234-5-2. OCLC 32895480.
- Shulgin, Alexander; Shulgin, Ann (1997). "DMT is Everywhere". TiHKAL: The Continuation. United States: Transform Press. p. 277. 0-9630096-9-9. OCLC 38503252.
- Gallimore, Andrew R.; Strassman, Rick J. (2016). "A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience". Frontiers in Pharmacology. 7 (211). :10.3389/fphar.2016.00211. 1663-9812. PMC . PMID 27471468.
- Strassman, Rick J. (1995). "Human psychopharmacology of N,N-dimethyltryptamine". Behavioural Brain Research. 73 (1-2): 121–124. :10.1016/0166-4328(96)00081-2. 1872-7549. 0166-4328. OCLC 06183451.
- "Erowid DMT Vault: Basics". Erowid. August 22, 2000. Retrieved January 7, 2020.
- Lüscher, Christian; Ungless, Mark A. (2006). "The Mechanistic Classification of Addictive Drugs". PLOS Medicine. 3 (11). :10.1371/journal.pmed.0030437. 1549-1277. PMID 17105338.
- Strassmann, Rick (1984). "Adverse reactions to psychedelic drugs. A review of the literature". Journal of Nervous and Mental Disease. 172 (10): 577–595. :10.1097/00005053-198410000-00001. 0022-3018. OCLC 1754691. PMID 6384428.
- "q21q21" (September 19, 2014). "Q21Q21 tek (and other limeteks) NOT recommended for shredded bark!". DMT Nexus. Retrieved January 8, 2020.
- Manske R. H. F. (1931). "A synthesis of the methyltryptamines and some derivatives". Canadian Journal of Research. 5 (5): 592–600. :10.1139/cjr31-097. 0366-6581.
- Bigwood J.; Ott J. (1977). "DMT: the fifteen minute trip". Head. 2 (4): 56–61. Archived from the original on January 27, 2006. Retrieved November 28, 2010.
- Strassman, R. J.; Qualls, C. R.; Uhlenhuth, E. H.; Kellner, R. (1994). "Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale" (PDF). Archives of General Psychiatry. 51 (2): 98–108. :10.1001/archpsyc.1994.03950020022002. 1538-3636. 2168-622X. PMID 8297217.
- Ott, Jonathan (1996). Pharmacotheon: Entheogenic Drugs, Their Plant Sources and History (2nd, densified ed.). Kennewick, WA: Natural Products. 978-0-9614234-9-0.
- Pachter I. J.; Zacharias D. E.; Ribeiro O. (1959). "Indole alkaloids of Acer saccharinum (the silver maple), Dictyoloma incanescens, Piptadenia colubrina, and Mimosa hostilis". The Journal of Organic Chemistry. 24 (9): 1285–87. :10.1021/jo01091a032. 1520-6904. 0022-3263.
- Fish M. S.; Johnson N. M.; Horning E. C. (1955). "Piptadenia alkaloids. Indole bases of P. peregrina (L.) Benth. and related species". Journal of the American Chemical Society. 72 (22): 5892–95. :10.1021/ja01627a034. 1520-5126. 0002-7863.
- Cimino G.; De Stefano S. (1978). "Chemistry of Mediterranean gorgonians: simple indole derivatives from Paramuricea chamaeleon". Comparative Biochemistry and Physiology C. 61 (2): 361–2. :10.1016/0306-4492(78)90070-9.
- Fontanilla, D.; Johannessen, M.; Hajipour, A. R.; Cozzi, N. V.; Jackson, M. B.; Ruoho, A. E. (2009). "The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator". Science. 323 (5916): 934–937. :10.1126/science.1166127. 1095-9203. 0036-8075. OCLC 1644869. PMC . PMID 19213917.
- Strassman, Rick J. (2001). DMT: The Spirit Molecule. A Doctor's Revolutionary Research into the Biology of Near-Death and Mystical Experiences. Rochester, Vt: Park Street. 978-0-89281-927-0. OCLC 45195642. ("Chapter summaries". Retrieved 27 February 2012.)
- Nichols, David E. (2018). "N,N-dimethyltryptamine and the pineal gland: Separating fact from myth". Journal of Psychopharmacology. :10.1177/0269881117736919. 1461-7285. 0269-8811. OCLC 19962867. PMID 29095071.
- "'Mystical' psychedelic compound found in normal brains". Neuroscience News. June 27, 2019. Retrieved January 8, 2020.
- Ly, Calvin; Greb, Alexandra C.; Cameron, Lindsay P.; Wong, Jonathan M.; Barragan, Eden V.; Wilson, Paige C.; Burbach, Kyle F.; Soltanzadeh Zarandi, Sina; Sood, Alexander; Paddy, Michael R.; Duim, Whitney C.; Dennis, Megan Y.; McAllister, A. Kimberley; Ori-McKenney, Kassandra M.; Gray, John A.; Olson, David E. (2018). "Psychedelics Promote Structural and Functional Neural Plasticity". Cell Reports. 23 (11): 3170–3182. :10.1016/j.celrep.2018.05.022. 2211-1247. PMID 29898390. PMC 6082376.
- Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. :10.1007/BF03161089. 1556-9039.
- "Convention On Psychotropic Substances, 1971" (PDF). United Nations Office on Drugs and Crime. Retrieved January 3, 2020.
- Herbert Schaepe (International Narcotics Control Board) (January 17, 2001). "International control of the preparation "ayahuasca"". Erowid. Retrieved January 8, 2020.
- "Poisons Standard December 2019". Federal Register of Legislation. Office of Parliamentary Counsel. November 14, 2019. Retrieved January 8, 2020.
- "RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016" (in Portuguese). Agência Nacional de Vigilância Sanitária [National Sanitary Surveillance Agency]. December 5, 2016. p. 22. Retrieved January 8, 2020.
- "Schedule III". Controlled Drugs and Substances Act (S.C. 1996, c. 19). Government of Canada. Retrieved January 1, 2020.
- "Bekendtgørelse om euforiserende stoffer - ni nye stoffer tilføjet" (in Danish). Danish Medicines Ageny. August 31, 2015. Retrieved January 1, 2020.
- "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Sechste Verordnung über die den Betäubungsmitteln gleichgestellten Stoffe" (PDF). Bundesgesetzblatt Jahrgang 1974 Teil I Nr. 6 (in German). Bundesanzeiger Verlag. January 23, 1974. pp. 97–98. Retrieved January 7, 2020.
- "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Tabella I" (PDF) (in Italian). Ministero della Salute [Ministry of Health]. p. 8. Retrieved January 7, 2020.
- "Schedule: Controlled Drugs". Misuse of Drugs Act, 1977. Government of Ireland. Retrieved January 8, 2020.
- "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020.
- "Opiumwet" (in Dutch). Ministerie van Binnenlandse Zaken en Koninkrijksrelaties [Ministry of the Interior and Kingdom Relations]. January 1, 2020. Retrieved January 8, 2020.
- "Schedule 1 Class A controlled drugs". "Reprint as at 13 August 2019: Misuse of Drugs Act 1975". Parliamentary Counsel Office. Retrieved January 7, 2020.
- "Постановление Правительства РФ от 30.06.1998 N 681 "Об утверждении перечня наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации" (с изменениями и дополнениями)" (in Russian). ГАРАНТ [GARANT]. Retrieved January 8, 2020.
- "Läkemedelsverkets författningssamling" (PDF) (in Swedish). Christina Rångemark Åkerman (Läkemedelsverket [Swedish Medical Products Agency]). September 21, 2011. p. 12. 1101-5225. Retrieved January 8, 2020.
- "Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved January 7, 2020.
- 1717 CheMall HE040533
- 1717 CheMall HE170155
- 1717 CheMall HE379832
- abcr AB460938
- ACToR: Aggregated Computational Toxicology Resource 61-50-7
- AKos AKOS005446117
- Alfa Chemistry 61-50-7
- American Custom Chemicals Corp CHM0069872
- Angene AGN-PC-0JK7GQ
- ApexBio B7404
- Aurora Fine Chemicals A18.034.067
- Aurora Fine Chemicals K05.114.926
- Biosynth D-5500
- CambridgeSoft Corporation 2933
- Cayman Chemical 13959
- Cayman Chemical 13959.0
- Cayman Chemical 15694
- Cayman Chemical 15694.0
- ChEBI CHEBI:28969
- ChemAdvisor OHS07780
- ChEMBL CHEMBL12420
- Chembo Pharma KB-296215
- ChemDB 4519410
- ChemDB 6750538
- ChemIDplus 000061507
- ChemIDplus 101831883
- ChemIDplus 61507
- Chemspace CSC015984723
- ChemSynthesis 20335
- Collaborative Drug Discovery 41408
- CSDeposition Service DB01488
- DiscoveryGate 4525689
- DiscoveryGate 58944
- DiscoveryGate 6089
- DrugBank DB01488
- DSigDB d4boss_662
- DSigDB d4ctd_5846
- DSigDB d4ttd_7603
- DTP/NCI 63795
- eMolecules 976831
- EPA DSSTox DTXCID4065313
- Erowid DMT
- FDA UNII - NLM UNII: WUB601BHAA
- FDA UNII - NLM WUB601BHAA
- Finetech Industry FT-0667348
- FooDB FDB023795
- Guide to PHARMACOLOGY 141
- Human Metabolome Database HMDB0005973
- Human Metabolome Database HMDB05973
- iChemical EBD21295
- Jean-Claude Bradley Open Melting Point Dataset 16741
- Jean-Claude Bradley Open Melting Point Dataset 21373
- Journal of Heterocyclic Chemistry 19660009_XXXVI
- KEGG C08302
- LabNetwork LN01288074
- Laboratory Chemical Safety Summary 6089
- LeadScope LS-82930
- MassBank JP003741
- MuseChem I010762
- NIAID 072305
- NIST Chemistry WebBook 1549698058
- NIST Spectra mainlib_352147
- NIST Spectra nist ri
- NIST Spectra replib_248091
- NIST Spectra replib_250700
- NIST Spectra replib_312935
- NIST Spectra replib_379568
- NIST Spectra replib_38693
- NMRShiftDB 10017644
- Parchem – fine & specialty chemicals 67379
- PubChem 6089
- PubMed 10090793
- PubMed 10350367
- PubMed 10372792
- PubMed 10404423
- PubMed 10438001
- PubMed 1057382
- PubMed 1057950
- PubMed 1058643
- PubMed 1059879
- PubMed 1062171
- PubMed 10637046
- PubMed 1064726
- PubMed 1066131
- PubMed 1067623
- PubMed 1068351
- PubMed 1069314
- PubMed 1070948
- PubMed 10940539
- PubMed 1095838
- PubMed 111285
- PubMed 11292011
- PubMed 11295326
- PubMed 116288
- PubMed 11763413
- PubMed 11900766
- PubMed 12361741
- PubMed 1275618
- PubMed 13384414
- PubMed 1354106
- PubMed 13685339
- PubMed 13914428
- PubMed 14138757
- PubMed 148665
- PubMed 15002845
- PubMed 15270248
- PubMed 15516287
- PubMed 15700647
- PubMed 15780487
- PubMed 16095048
- PubMed 16149327
- PubMed 16149328
- PubMed 16342002
- PubMed 16356341
- PubMed 16460788
- PubMed 16575552
- PubMed 17159796
- PubMed 17211054
- PubMed 17238112
- PubMed 17239595
- PubMed 17269042
- PubMed 17310474
- PubMed 17591658
- PubMed 1941365
- PubMed 1941625
- PubMed 2103707
- PubMed 2201522
- PubMed 22091
- PubMed 2268688
- PubMed 238721
- PubMed 266219
- PubMed 266950
- PubMed 267501
- PubMed 270770
- PubMed 271513
- PubMed 271755
- PubMed 276408
- PubMed 276891
- PubMed 278843
- PubMed 279544
- PubMed 279938
- PubMed 2828913
- PubMed 284199
- PubMed 284722
- PubMed 292978
- PubMed 3006089
- PubMed 329291
- PubMed 3350047
- PubMed 3455825
- PubMed 3472525
- PubMed 3472526
- PubMed 3475068
- PubMed 3481368
- PubMed 3489620
- PubMed 3801784
- PubMed 3858911
- PubMed 3866749
- PubMed 3867833
- PubMed 4041865
- PubMed 4056789
- PubMed 407597
- PubMed 41604
- PubMed 4196867
- PubMed 4358118
- PubMed 4517484
- PubMed 4518592
- PubMed 4519415
- PubMed 4520847
- PubMed 4527540
- PubMed 4533618
- PubMed 4582927
- PubMed 4607811
- PubMed 4696887
- PubMed 4927758
- PubMed 5031115
- PubMed 5053241
- PubMed 5064096
- PubMed 5077140
- PubMed 5081369
- PubMed 510375
- PubMed 5151243
- PubMed 5483205
- PubMed 5535408
- PubMed 5698438
- PubMed 5760624
- PubMed 5834159
- PubMed 5839067
- PubMed 5839429
- PubMed 6052683
- PubMed 6102916
- PubMed 6109775
- PubMed 6144308
- PubMed 6413999
- PubMed 6521493
- PubMed 6577915
- PubMed 6579573
- PubMed 6581313
- PubMed 6587171
- PubMed 6587850
- PubMed 6588281
- PubMed 6641790
- PubMed 6769527
- PubMed 6770869
- PubMed 6793698
- PubMed 6798607
- PubMed 6798611
- PubMed 7005
- PubMed 7086824
- PubMed 731434
- PubMed 7905222
- PubMed 7905821
- PubMed 803203
- PubMed 8297216
- PubMed 8297217
- PubMed 9447860
- PubMed 9468359
- PubMed 9682278
- PubMed 9768567
- PubMed 9852119
- Royal Society of Chemistry b9nj00577c
- Royal Society of Chemistry c1md00044f
- RSC Learn Chemistry Wiki N,N-Dimethyltryptamine
- Sabio-RK 10401
- Serum Metabolome Database HMDB0005973
- Sigma-Aldrich CERILLIAN-D-102
- Sigma-Aldrich D-102
- Sigma-Aldrich SIGMA-SML0791
- Sigma-Aldrich SML0791
- SORD SST0049979
- Springer Nature 5-HT agonist induced analgesia modulated by central but not peripheral noradrenaline depletion in rats
- Springer Nature A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity
- Springer Nature A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 ??-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches
- Springer Nature Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users
- Springer Nature Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors
- Springer Nature An observational study of hallucinogen-induced behavior in unrestrained Macaca mulatta
- Springer Nature Ayahuasca and Kambo intoxication after alternative natural therapy for depression, confirmed by mass spectrometry
- Springer Nature Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
- Springer Nature Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015
- Springer Nature Behavioral effects of ??,??,??,??-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor
- Springer Nature Biological activities of some 5-substituted N,N-dimethyltryptamines, ??-methyltryptamines, and gramines
- Springer Nature Blood and urine levels of N,N-dimethyltryptamine following administration of psychoactive dosages to human subjects
- Springer Nature Commentary on: Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance by Griffiths et al.
- Springer Nature Comparison of a placebo, N-dimethyltryptamine, and 6-hydroxy-N-dimethyltryptamine in man
- Springer Nature Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats
- Springer Nature Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers
- Springer Nature Dimethyltryptamin: Its metabolism in man; the relation of its psychotic effect to the serotonin metabolism
- Springer Nature Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter
- Springer Nature Dimethyltryptamine levels in blood of schizophrenic patients and control subjects
- Springer Nature Discriminative stimulus effects of N,N-diisopropyltryptamine
- Springer Nature Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively
- Springer Nature Effects of pargyline and SKF-525A on brain N,N-dimethyltryptamine concentrations and hyperactivity in mice
- Springer Nature Effects of psychotropic drugs on open-field behaviour in rats
- Springer Nature Effects of selected opioid agonists and antagonists on DMT-and LSD-25-induced disruption of food-rewarded bar pressing behavior in the rat
- Springer Nature Electroencephalographic studies on the development of tolerance and cross tolerance to mescaline in the rat
- Springer Nature Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities
- Springer Nature Factors affecting the urinary excretion of endogenously formed dimethyltryptamine in normal human subjects
- Springer Nature Gas chromatographic-mass spectrometric isotope dilution determination of N,N-dimethyltryptamine concentrations in normals and psychiatric patients
- Springer Nature Hallucinogenic agents as discriminative stimuli: A correlation with serotonin receptor affinities
- Springer Nature Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex
- Springer Nature High specific activity tritium labelling of some sigma-1 receptor agonists
- Springer Nature High-affinity 3H-serotonin binding to caudate: Inhibition by hallucinogens and serotoninergic drugs
- Springer Nature Hydroxylation and N-demethylation of N,N-dimethyltryptamine
- Springer Nature Immunohistochemical and behavioral analysis of spinal lesions induced by a substance P antagonist and protection by thyrotropin releasing hormone
- Springer Nature In vivo kinetics and displacement study of a carbon-11-labeled hallucinogen, N,N-[11C]dimethyltryptamine
- Springer Nature Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant
- Springer Nature Interaction of synthetic opioid metenkephalin peptide analogs, lilly 127623 and FK 33-824 with indole hallucinogens: Antagonism of N,N-dimethyltryptamine- and LSD-induced disruption of food-rewarded bar pressing behavior in the rat
- Springer Nature LDH isoenzyme spectrum in the myocardium of rats after repeated doses of isoproterenol
- Springer Nature Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro
- Springer Nature Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis
- Springer Nature Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors
- Springer Nature Myo-inositol attenuates the enhancement of the serotonin syndrome by lithium
- Springer Nature N-dimethylated indoleamines in blood of acute schizophrenics
- Springer Nature Naloxone enhancement of DMT and LSD-25 induced suppression of food-rewarded bar pressing behavior in the rat
- Springer Nature Neurochemical investigations of the interaction of N,N-dimethyltryptamine with the dopaminergic system in rat brain
- Springer Nature Neurotheologie
- Springer Nature New fluorophore-forming reactions for histochemical visualization of N-acetylated and tertiary indolamines using glyoxylic acid, aluminum-formaldehyde and trifluoroacetic acid anhydride as reagents
- Springer Nature On the transmethylation hypothesis: stress, N,N-dimethyltryptamine, and positive symptoms of psychosis
- Springer Nature Pharmacological evidence of neuro-pharmacological activity of Acacia tortilis leaves in mice
- Springer Nature Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis
- Springer Nature Pharmacology of ayahuasca administered in two repeated doses
- Springer Nature Phenelzine withdrawal
- Springer Nature Platelet serotonin uptake sites increased in drinkers ofayahuasca
- Springer Nature Receptors for 5-hydroxytryptamine on the sympathetic nerves of the rabbit heart
- Springer Nature Relative potency of amphetamine derivatives and N,N-dimethyltryptamines
- Springer Nature Severe aggression in rats induced by mescaline but not other hallucinogens
- Springer Nature Stimulation of rat prolactin secretion by indolealkylamine hallucinogens
- Springer Nature Structure activity relations of some indolealkylamines in comparison to phenethylamines on motor activity and acquisition of avoidance behavior
- Springer Nature Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers
- Springer Nature Substituierte t-Hexylamine als neuer Typ hypotensiv wirksamer Verbindungen
- Springer Nature Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report
- Springer Nature The effect of MAO inhibition on the experimental psychosis induced by dimethyltryptamin
- Springer Nature The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide
- Springer Nature The effects of 5-hydroxytryptamine and some related compounds on the cat superior cervical ganglion in situ
- Springer Nature The effects of N,N-dimethyltryptamine on operant behavior in squirrel monkeys
- Springer Nature The hallucinogenic world of tryptamines: an updated review
- Springer Nature The inhibition of the cage-leaving responseu2014A model for studies of the serotonergic neurotransmission in the rat
- Springer Nature The psychedelic properties of banana peel: an appraisal
- Springer Nature The role of 5-HT2A, 5-HT2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice
- Springer Nature Vergleich ver??nderter Bewu??tseinszust??nde unter den Halluzinogenen (???)-??9-trans-Tetrahydrocannabinol (??9-THC) und N,N-Dimethyltryptamin (DMT)
- SynQuest 3H32-1-0R
- The Merck Index Online cs000000007449
- Thieme Chemistry SD-110-00020
- Thomson Pharma 00483902
- Thoreauchem TH-B00149
- Tocris Bioscience 3428
- Tractus Company Limited
- Urine Metabolome Database HMDB0005973
- VulcanChem VC009379
- Wikidata Q407217
- Wikipedia Dimethyltryptamine
- Wikipedia N,N-Dimethyltryptamine
- xPharm 9015
- ZINC ZINC00897457
Information made possible with:
- PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
- Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
- PubChem National Center for Bio Informatics
- Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
Additional APIs were used to construct this information. Thanks to ChemSpider, NCBI, PubChem etc.
Data is constantly updated so please check back later to see if there is any more available information on this substance.